Introduction:Fusobacterium nucleatum, a common oral microbe associated with periodontal disease, has emerged as a significant prognostic indicator in colorectal cancer (CRC). This organism is notably enriched in CRC tissues and is associated with reduced survival times and relapse. Fusobacterium is implicated in encouraging the development of chemoresistance through diverse tumor-promoting pathways that are increasingly being elucidated across molecular domains. Methods: This work uses a combined analysis of public data examining the role ofF. nucleatumin CRC by investigating multiple transcriptomic datasets derived from co-culture infections in vitro. Results: In tandem with previously identified mechanisms known to be influenced byF. nucleatum, this analysis revealed that the bacterium activates multiple chemoresistance-associated pathways, including those driving inflammation, immune evasion, DNA damage, and metastasis. Notably, this study uncovered a novel induction of type I and type II interferon signaling, suggesting activation of a pseudo-antiviral state. Furthermore, pathway analysis (IPA) predicted altered regulation of several therapeutic agents, suggesting thatF. nucleatummay compromise drug efficacy through transcriptional reprogramming. Conclusions: These findings reinforce the role ofF. nucleatumin modulating host cellular pathways and support the hypothesis that bacterial association potentiates chemoresistance.
引言：具核梭杆菌是一种与牙周病相关的常见口腔微生物，现已成为结直肠癌的重要预后指标。该菌在结直肠癌组织中显著富集，并与生存期缩短及复发风险增加相关。研究表明，具核梭杆菌通过多种促癌途径促进化疗耐药性的形成，这些分子层面的作用机制正日益明晰。方法：本研究通过分析体外共培养感染产生的多组转录组数据集，对公共数据进行整合分析，以探究具核梭杆菌在结直肠癌中的作用。结果：结合既往已知的具核梭杆菌作用机制，本分析揭示该菌可激活多条化疗耐药相关通路，包括驱动炎症反应、免疫逃逸、DNA损伤及转移的途径。值得注意的是，本研究首次发现该菌能诱导I型和II型干扰素信号传导，提示其可能激活类抗病毒状态。此外，通路分析预测多种治疗药物的调控会发生改变，表明具核梭杆菌可能通过转录重编程影响药物疗效。结论：这些发现进一步证实了具核梭杆菌在调控宿主细胞通路中的作用，支持了细菌感染可能增强化疗耐药性的假说。
肿瘤(癌症)患者之家